Conclusion Results showed that a low NLR before treatment could predict a good response to RT or CCRT at all stages of uterine cervical cancer. The NLR may be a promising parameter on which to base the choice of a therapeutic strategy to treat SCC of the uterine cervix.
Introduction
Even though the incidence and mortality of invasive uterine cervical cancer have steadily decreased, this disease is still the second most common type of cancer in females worldwide and the leading cause of cancer deaths in women in developing countries [1] .
The neutrophil-to-lymphocyte ratio (NLR) has been used as a cost-effective and simple parameter to indicate systemic inflammation or stress in critically ill patients without cancer [2] . The NLR may also relate to the prognosis of many types of cancer, including gastrointestinal tract malignancies [3] , hepatocellular cancer [4] , pancreatic cancer [5] , non-small cell lung cancer [6] , and urinary cancer [7] . Furthermore, the pretreatment NLR predicts survival in epithelial ovarian cancer [8] and uterine cervical cancer [9, 10] . However, the NLR was not a predictive factor in patients with uterine cervical cancer treated with neoadjuvant chemotherapy and radical hysterectomy [11] . Thus, the clinical implications of the NLR have yet to be determined.
Despite the improved survival rate for patients who receive concurrent chemoradiation therapy (CCRT) [12] , some patients are resistant to this treatment. The aim of this
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study was to investigate the prognostic role of the NLR as a pretreatment marker prior to treatment of uterine cervical cancer with radiation therapy (RT) alone or CCRT.
Methods

Patients
Records of patients who had stage IB1 to IV uterine cervical cancer according to the staging system of the International Federation of Gynecology and Obstetrics (FIGO) were retrospectively reviewed using electronic databases. These patients were histologically diagnosed with squamous cell carcinoma (SCC) and underwent RT or CCRT at Hirosaki University Hospital from 2005−2013. We excluded 6 patients in whom the differential white blood cell (WBC) count was not determined, 5 patients who had to be treated for another inflammatory disease just prior to RT or CCRT, and 1 patient who had previously undergone RT at another hospital. This study ultimately examined the records of 56 patients.
Treatment
RT-External beam radiation was delivered using anterior and posterior parallel opposed fields (AP-PA fields) or a four-field box technique (AP-PA and two lateral fields) generated by a linear accelerator (Varian Medical System, USA) with an energy of 10 or 15 MV photon beams. Whole pelvis irradiation with a total isocentric dose of 45-50 Gy was delivered with a fraction size of 1.8-2 Gy per day for 5 days per week over a 5-week period. After a dose of approximately 20 or 30 Gy, a central shield with a width of 4 cm at the midline was inserted and high-dose rate intracavitary brachytherapy was performed using a microselectron HDR (Nucletron, Netherlands) with an Ir-192 source. Intracavitary brachytherapy, with a fraction size of 6 Gy delivered to point A, was performed once a week for a total of 3-4 times.
Chemotherapy-Thirty mg/m 2 of nedaplatin was dissolved in a 500-mL saline solution and infused intravenously over 180 min. The first round was administered on the day that external beam RT started. The regimen was repeated weekly for a total of 6 times. Nedaplatin infusion was completed 1 h before irradiation [13] . The median number of weekly chemotherapy cycles was 5.4.
Outcomes
The primary statistical endpoint was tumor response, which was assessed by means of a clinical examination, including histological examination of the uterine cervix and a computed tomography (CT) scan from the chest to the pelvis. These examinations were performed approximately 1 month after completion of RT or CCRT. Patients with no evidence of disease were considered to have a clinical complete response (CR). If tumors shrank after treatment but cancer cells or tumors were still noted, the patient was not considered to have a CR.
Progression-free survival (PFS) was defined as the time between the date of the completion of treatment and the date of identification of progressive disease. Progressive disease was defined when (1) relapse of the primary lesion was microscopically confined in patients with CR, (2) the primary lesion showed at least a 20 % increase of the longest dimension using magnetic resonance imaging or CT in patients without CR, (3) pelvic lymphadenopathy or one or more new lesions were noted using CT in patients with and without CR, and (4) progressive disease was not declared on the basis of tumor marker alone. Overall survival (OS) was defined as the time between the date of completion of treatment and the date of death.
Calculation of the NLR and determination of the NLR cut-off level
The NLR was defined as the absolute neutrophil count divided by the absolute lymphocyte count. Before treatment, the median NLR was 2.4, and patients were divided into a high NLR group (≥2.5) and a low NLR group (<2.5).
Statistical analysis
The following variables were analyzed to predict tumor response and survival-FIGO stage, tumor size, treatment (patients were grouped as RT alone or CCRT), baseline hemoglobin (Hb) level, baseline WBC and lymphocyte counts, and the NLR. The chi-squared test and Student's t test were used to analyze categorical data, and the Welsh test was used for continuous variables. Receiver opening characteristic plots were conducted to determine the maximum sensitivity and specificity of a threshold value to stratify patients at high risk of recurrence. The relationships between NLR and WBC, neutrophil and lymphocyte counts were calculated using Spearman's rank correlation coefficient.
Multiple logistic regression models were used to identify independent prognostic factors for a response and PFS. The following factors were included in the multivariable models-age, FIGO stage, pretreatment SCC value, tumor size, baseline neutrophil and lymphocyte counts, Hb level, and the NLR.
The OS and PFS were calculated using the KaplanMeier method. A log-rank test was used to assess statistical significance. All P values were two-tailed and P < 0.05 was considered statistically significant. All statistical analyses were performed using SPSS (version 21, SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
This study analyzed data from 56 patients with a median age of 65.1 years (range 35-89 years). In terms of FIGO stage, 13 patients had stage I cancer, 11 had stage II, 17 had stage III, and 15 had stage IV. Of these 56 patients, 35 were in the high NLR group and 21 were in the low NLR group. He clinical characteristics of the patients and tumors by the pretreatment NLR are shown in Table 1 . As seen in this Table, patients with ≥2.5 NLR had an advanced tumor in terms of tumor size, SCC level and lymph node metastasis. Figure 1 shows the actual values of NLR according to stage I/II and III/IV.
When this analysis was performed, clinical outcomes were recorded for all patients except for 2 who had been followed until recurrence. Cancer recurred in 20 patients (35.7 %) and 16 patients (28.6 %) died due to the cancer. The mean period to recurrence was 5.3 months (range 1-18 months) and the mean period to disease-related death was 14.2 months (range 2-41 months). At completion of treatment, 25 patients (44.6 %) had a clinical CR. Table 2 shows the relationship between pretreatment factors and CR obtained from our patients. As shown in Table 2 , univariate logistic regression analysis found a significant association between CR and FIGO stage, tumor size, type of treatment, WBC count, neutrophil count and NLR. In this study, a higher baseline neutrophil count was also a significant predictor of non-response (Table 2) . In comparison to a high NLR, a low NLR was significantly associated with a CR (P < 0.00005) ( Table 3) . When cancer was divided into stages I/II and III/IV, patients with a low NLR had a significantly better therapeutic outcome than those with a high NLR (Table 3 ).
In multivariate logistic regression analysis with regard to CR, variables that were considered to be statistically significant factors in univariate regression were selected. These variables were FIGO stage, tumor size, treatment, and the NLR. The pretreatment NLR was closely correlated with the pretreatment WBC count and neutrophil count, as indicated by Spearman's rank correlation coefficients (Table 4) . Of the variables (WBC count, neutrophil count, and the NLR) only the NLR was selected as the most significant factor (P = 0.0015) because of multicollinearity. Multivariate logistic regression revealed that the NLR was a significant prognostic factor with an odds ratio of 0.35 (95 % confidence interval 0.17-0.74, Table 5 ). Receiver operating characteristic (ROC) curves were derived for age, SCC, tumor size, NLR, and Hb levels with CR as an explanatory variable. Examination of the parameters with the largest positive likelihood ratios indicated that a cut-off level of 2.5 for the NLR had the largest positive likelihood ratio. This level was close to the median NLR (Table 6) . The relationship between pretreatment factors and PFS and OS Univariate and multivariate analyses revealed that only the NLR was a significant prognostic factor for PFS and OS (Tables 7, 8 ). Patients with a high NLR had a significantly shorter PFS and OS than those with a low NLR (Fig. 2a, b) . The pretreatment Hb level was closely associated with PFS (P = 0.058) ( Table 8) .
Discussion
Previous studies [14, 15] have shown that FIGO stage, Hb level, and tumor size are significant prognostic factors of cervical cancer and the results of the present study were compatible, as shown in Table 1 . In addition, treatment modality (CCRT vs RT) was also reported to be an impact prognostic factor, as CCRT had a higher rate of success than RT alone [12] . The present study showed that the pretreatment NLR was significantly related to the outcomes of radiation for uterine cervical cancer, and supported results shown by Lee et al. [9] and Zhang et al. [10] . In addition, the present study showed that a low NLR (<2.5) was significantly associated with a CR and longer PFS and OS in comparison to a high NLR (≥2.5). It has been reported that a high NLR is a factor for a poor prognosis after surgery or after chemotherapy in relation to various types of carcinomas [3] [4] [5] [6] [7] [8] [9] [10] . Regarding cervical cancer, Lee et al. [9] reported that the NLR may be a predictor of prognosis for RT after surgery or definitive RT. Although the current study involved a choice of only RT or CCRT to treat cervical cancer, the results were similar to those of Lee et al.
An increase in neutrophils or a decrease in lymphocytes is reported to be associated with a shorter survival time. The specific mechanisms as to why a high NLR diminishes the effectiveness of therapy and why it increases recurrence and predicts a poor prognosis have yet to be identified. A G-CSF-producing tumor is typically characterized by rapid progression and obvious leukocytosis, resulting in a poor prognosis. In 4 patients with G-CSF-producing cervical cancer, Matsumoto et al. [16] reported that the cancer recurred in all 4 patients within 6 months and that all of the patients died within 15 months. In addition, the presence of inflammatory foci may increase the risk of cancer progression. Inflammation is known to change the microenvironment of a tumor and promote angiogenesis and metastasis [17] . Inflammatory changes are normally accompanied by an increase in neutrophils. Therefore, one could logically predict that cervical cancer and associated leukocytosis would have a poor prognosis. Recently, an explanation for the poor prognosis of cervical cancer and associated leukocytosis has been proposed. G-CSF is produced by a tumor and in turn induces the production of myeloidderived suppressor cells (MDSCs). These MDSCs cause rapid progression of cervical cancer and leukocytosis and radioresistance [18] . Mabuchi et al. [18] depleted MDSCs, which succeeded in inhibiting the progression of cervical cancer and leukocytosis and enhancing radiosensitivity. MDSCs have been found in bone marrow, blood, and the spleen of individuals with tumors. In response to the progression of inflammation and cancer, these cells spread throughout the body as part of the host's immune response [19] . Although cisplatin is a key drug in CCRT to treat cervical cancer, a study has reported that it induces MDSCs [20] . However, gemcitabine is known to be an anticancer drug that reduces the number of MDSCs [21] ; therefore, gemcitabine may be favorable for chemoradiation therapy of cervical cancer patients with high NLR. Recent studies have found increased levels of proinflammatory cytokines in patients with an increased NLR [22, 23] and increased peri-tumor macrophage infiltration [24] . These results suggest that an increased NLR reflects an up-regulated innate immune response [21] . The immune response has been found to differ depending on the type of cancer. With pancreatic cancer, a marked increase in lymphocytes occurs preoperatively and postoperatively [25] . The NLR was not associated with the prognosis of pancreatic cancer. In addition, a study has reported that combining chemotherapy and polysaccharide K (PSK) after surgery for colon cancer allows the NLR (which is correlated with prognosis) to be kept to a low level, improving the patient's prognosis [26] . Chemotherapy triggers the apoptosis of peripheral blood T lymphocytes, but immunotherapy with PSK is presumably effective because it controls that apoptosis [27] .
RT is known to primarily have little effect in a hypoxic state. A hypoxic state is related to inflammation and anemia, and elements of the innate inflammatory response are associated with the up-regulation of growth factors and angiogenesis [28, 29] . Systemic inflammatory responses are associated with alteration in the circulating WBC count, with neutrophilia and relative lymphopenia [30] . Santin et al. [31] investigated lymphocyte populations including CD3+, CD4+ and CD8+ T-cell subsets, B cells (CD19+), and natural killer cells (CD56+, CD16+, CD3−) before, during, and after RT in patients with locally advanced cervical cancer. While both RT and CCRT with cisplatin significantly decreased the mean absolute number of all lymphocyte subsets compared to pretreatment levels, Santin et al. detected no differences in the characteristics or the magnitude of the lymphopenia induced by the two treatments. Thus, cisplatin does not enhance the magnitude or characteristics of radiationinduced immunosuppression [31] .
In conclusion, the current study showed that a low NLR before treatment could predict a good response to RT or CCRT bat all stages of uterine cervical cancer. The NLR may be a promising parameter on which to base the choice of a therapeutic strategy to treat SCC of the uterine cervix.
This study involved a relatively small sample size, so further validation is required prior to incorporating the NLR as a prognostic indicator. Patients with a high NLR had a significantly shorter PFS than those with a low NLR (log-rank test, P < 0.05). b Kaplan-Meier survival curves for overall survival (OS) of patients with a high NLR and those with a low NLR. Patients with a high NLR had a significantly shorter OS than those with a low NLR (log-rank test, P < 0.001)
